Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2014

Open Access 01-12-2014 | Primary research

High threshold of β1 integrin inhibition required to block collagen I-induced membrane type-1 matrix metalloproteinase (MT1-MMP) activation of matrix metalloproteinase 2 (MMP-2)

Authors: Kulrut Borrirukwanit, Prasit Pavasant, Tony Blick, Marc A Lafleur, Erik W Thompson

Published in: Cancer Cell International | Issue 1/2014

Login to get access

Abstract

Background

Matrix metalloproteinase-2 (MMP-2) is an endopeptidase that facilitates extracellular matrix remodeling and molecular regulation, and is implicated in tumor metastasis. Type I collagen (Col I) regulates the activation of MMP-2 through both transcriptional and post-transcriptional means; however gaps remain in our understanding of the involvement of collagen-binding β1 integrins in collagen-stimulated MMP-2 activation.

Methods

Three β1 integrin siRNAs were used to elucidate the involvement of β1 integrins in the Col I-induced MMP-2 activation mechanism. were used to elucidate the involvement of1 integrin knockdown was analyzed by quantitative RT-PCR, Western Blot and FACS analysis. Adhesion assay and collagen gel contraction were used to test the biological effects of β1 integrin abrogation. MMP-2 activation levels were monitored by gelatin zymography.

Results

All three β1 integrin siRNAs were efficient at β1 integrin knockdown and FACS analysis revealed commensurate reductions of integrins α2 and α3, which are heterodimeric partners of β1, but not αV, which is not. All three β1 integrin siRNAs inhibited adhesion and collagen gel contraction, however only the siRNA showing the greatest magnitude of β1 knockdown inhibited Col I-induced MMP-2 activation and reduced the accompanying upregulation of MT1-MMP, suggesting a dose response threshold effect. Re-transfection with codon-swapped β1 integrin overcame the reduction in MMP-2 activation induced by Col-1, confirming the β1 integrin target specificity. MMP-2 activation induced by TPA or Concanavalin A (Con A) was not inhibited by β1 integrin siRNA knockdown.

Conclusion

Together, the data reveals that strong abrogation of β1 integrin is required to block MMP-2 activation induced by Col I, which may have implications for the therapeutic targeting of β1 integrin.
Appendix
Available only for authorised users
Literature
1.
2.
Schatzmann F, Marlow R, Streuli CH: Integrin signaling and mammary cell function. J Mammary Gland Biol Neoplasia. 2003, 8: 395-408. 10.1023/B:JOMG.0000017427.14751.8c.CrossRefPubMed
3.
Elliott BE, Ekblom P, Pross H, Niemann A, Rubin K: Anti-beta 1 integrin IgG inhibits pulmonary macrometastasis and the size of micrometastases from a murine mammary carcinoma. Cell Adhes Commun. 1994, 1: 319-332. 10.3109/15419069409097263.CrossRefPubMed
4.
Fujita S, Watanabe M, Kubota T, Teramoto T, Kitajima M: Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett. 1995, 91: 145-149. 10.1016/0304-3835(95)03735-F.CrossRefPubMed
5.
Cordes N, Park CC: beta1 integrin as a molecular therapeutic target. Int J Radiat Biol. 2007, 83: 753-760. 10.1080/09553000701639694.CrossRefPubMed
6.
Lynch CC, Matrisian LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation. 2002, 70: 561-573. 10.1046/j.1432-0436.2002.700909.x.CrossRefPubMed
7.
Overall CM, Kleifeld O: Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006, 6: 227-239. 10.1038/nrc1821.CrossRefPubMed
8.
Fingleton B: Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci. 2006, 11: 479-491. 10.2741/1811.CrossRefPubMed
9.
Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2: 161-174. 10.1038/nrc745.CrossRefPubMed
10.
Noel AC, Polette M, Lewalle JM, Munaut C, Emonard HP, Birembaut P, Foidart JM: Coordinate enhancement of gelatinase A mRNA and activity levels in human fibroblasts in response to breast-adenocarcinoma cells. Int J Cancer. 1994, 56: 331-336. 10.1002/ijc.2910560306.CrossRefPubMed
11.
Dalberg K, Eriksson E, Enberg U, Kjellman M, Backdahl M: Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: correlation with invasive growth of breast cancer. World J Surg. 2000, 24: 334-340. 10.1007/S002689910053.CrossRefPubMed
12.
Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003, 92: 827-839. 10.1161/01.RES.0000070112.80711.3D.CrossRefPubMed
13.
Itoh Y, Seiki M: MT1-MMP: an enzyme with multidimensional regulation. Trends Biochem Sci. 2004, 29: 285-289. 10.1016/j.tibs.2004.04.001.CrossRefPubMed
14.
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994, 370: 61-65. 10.1038/370061a0.CrossRefPubMed
15.
Sato H, Takino T, Kinoshita T, Imai K, Okada Y, Stetler Stevenson WG, Seiki M: Cell surface binding and activation of gelatinase A induced by expression of membrane-type-1-matrix metalloproteinase (MT1-MMP). FEBS Lett. 1996, 385: 238-240. 10.1016/0014-5793(96)00389-4.CrossRefPubMed
16.
Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kda type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995, 270: 5331-5338. 10.1074/jbc.270.10.5331.CrossRefPubMed
17.
Azzam HS, Thompson EW: Collagen-induced activation of the M(r) 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res. 1992, 52: 4540-4544.PubMed
18.
Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, Pulyaeva H, Tamborlane JW, Tirgari R, Wapnir I, Azzam H: Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res Treat. 1994, 31: 357-370. 10.1007/BF00666168.CrossRefPubMed
19.
Haas TL, Davis SJ, Madri JA: Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem. 1998, 273: 3604-3610. 10.1074/jbc.273.6.3604.CrossRefPubMed
20.
Deryugina EI, Bourdon MA, Reisfeld RA, Strongin A: Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res. 1998, 58: 3743-3750.PubMed
21.
Ellerbroek SM, Wu YI, Overall CM, Stack MS: Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J Biol Chem. 2001, 276: 24833-24842. 10.1074/jbc.M005631200.CrossRefPubMed
22.
Kim IY, Jeong SJ, Kim ES, Kim SH, Moon A: Type I collagen-induced pro-MMP-2 activation is differentially regulated by H-Ras and N-Ras in human breast epithelial cells. J Biochem Mol Biol. 2007, 40: 825-831. 10.5483/BMBRep.2007.40.5.825.CrossRefPubMed
23.
Gilles C, Polette M, Seiki M, Birembaut P, Thompson EW: Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. LabInvest. 1997, 76: 651-660.
24.
Lafleur MA, Mercuri FA, Ruangpanit N, Seiki M, Sato H, Thompson EW: Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain. J Biol Chem. 2006, 281: 6826-6840. 10.1074/jbc.M513084200.CrossRefPubMed
25.
Prockop DJ, Kivirikko KI: Collagens: molecular biology, diseases, and potentials for therapy. Annu Rev Biochem. 1995, 64: 403-434. 10.1146/annurev.bi.64.070195.002155.CrossRefPubMed
26.
27.
Jokinen J, Dadu E, Nykvist P, Kapyla J, White DJ, Ivaska J, Vehvilainen P, Reunanen H, Larjava H, Hakkinen L, Heino J: Integrin-mediated cell adhesion to type I collagen fibrils. J Biol Chem. 2004, 279: 31956-31963. 10.1074/jbc.M401409200.CrossRefPubMed
28.
Ellerbroek SM, Fishman DA, Kearns AS, Bafetti LM, Stack MS: Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. Cancer Res. 1999, 59: 1635-1641.PubMed
29.
Tang Y, Rowe RG, Botvinick EL, Kurup A, Putnam AJ, Seiki M, Weaver VM, Keller ET, Goldstein S, Dai J, Begun D, Saunders T, Weiss SJ: MT1-MMP-dependent control of skeletal stem cell commitment via a β1-integrin/YAP/TAZ signaling axis. Dev Cell. 2013, 25: 402-416. 10.1016/j.devcel.2013.04.011.CrossRefPubMedCentralPubMed
30.
Mori H, Lo AT, Inman JL, Alcaraz J, Ghajar CM, Mott JD, Nelson CM, Chen CS, Zhang H, Bascom JL, Seiki M, Bissell MJ: Transmembrane/cytoplasmic, rather than catalytic, domains of Mmp14 signal to MAPK activation and mammary branching morphogenesis via binding to integrin β1. Development. 2013, 140: 343-352. 10.1242/dev.084236.CrossRefPubMedCentralPubMed
31.
Sakai K, Nakamura T, Suzuki Y, Imizu T, Matsumoto K: 3-D collagen-dependent cell surface expression of MT1-MMP and MMP-2 activation regardless of integrin beta1 function and matrix stiffness. Biochem Biophys Res Commun. 2011, 412: 98-103. 10.1016/j.bbrc.2011.07.050.CrossRefPubMed
32.
Pulyaeva H, Bueno J, Polette M, Birembaut P, Sato H, Seiki M, Thompson EW: MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. Clin Exp Metastasis. 1997, 15: 111-120. 10.1023/A:1018444609098.CrossRefPubMed
33.
Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW: SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998, 58: 5529-5536.PubMed
34.
Lafleur MA, Drew AF, de Sousa EL, Blick T, Bills M, Walker EC, Williams ED, Waltham M, Thompson EW: Upregulation of matrix metalloproteinases (MMPs) in breast cancer xenografts: a major induction of stromal MMP-13. Int J Cancer. 2005, 114: 544-554. 10.1002/ijc.20763.CrossRefPubMed
35.
Tulla M, Pentikainen OT, Viitasalo T, Kapyla J, Impola U, Nykvist P, Nissinen L, Johnson MS, Heino J: Selective binding of collagen subtypes by integrin alpha 1I, alpha 2I, and alpha 10I domains. J Biol Chem. 2001, 276: 48206-48212.PubMed
36.
Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell. 2002, 110: 673-687. 10.1016/S0092-8674(02)00971-6.CrossRefPubMed
37.
Green LJ, Mould AP, Humphries MJ: The integrin beta subunit. Int J Biochem Cell Biol. 1998, 30: 179-184. 10.1016/S1357-2725(97)00107-6.CrossRefPubMed
38.
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999, 99: 81-92. 10.1016/S0092-8674(00)80064-1.CrossRefPubMed
39.
Ruangpanit N, Chan D, Holmbeck K, Birkedal-Hansen H, Polarek J, Yang C, Bateman JF, Thompson EW: Gelatinase A (MMP-2) activation by skin fibroblasts: dependence on MT1-MMP expression and fibrillar collagen form. Matrix Biol. 2001, 20: 193-203. 10.1016/S0945-053X(01)00135-4.CrossRefPubMed
40.
41.
Lipardi C, Wei Q, Paterson BM: RNAi as random degradative PCR. siRNA primers convert mRNA into dsRNA that are degraded to generate new siRNAs. Cell. 2001, 107: 297-307. 10.1016/S0092-8674(01)00537-2.CrossRefPubMed
42.
Guo W, Giancotti FG: Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004, 5: 816-826. 10.1038/nrm1490.CrossRefPubMed
43.
Larsen M, Artym VV, Green JA, Yamada KM: The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol. 2006, 18: 463-471. 10.1016/j.ceb.2006.08.009.CrossRefPubMed
44.
Ivaska J, Reunanen H, Westermarck J, Koivisto L, Kahari VM, Heino J: Integrin alpha2beta1 mediates isoform-specific activation of p38 and upregulation of collagen gene transcription by a mechanism involving the alpha2 cytoplasmic tail. J Cell Biol. 1999, 147: 401-416. 10.1083/jcb.147.2.401.CrossRefPubMedCentralPubMed
45.
Galvez BG, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo AG: ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol. 2002, 159: 509-521. 10.1083/jcb.200205026.CrossRefPubMedCentralPubMed
46.
Lehti K, Lohi J, Juntunen MM, Pei D, Keski-Oja J: Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J Biol Chem. 2002, 277: 8440-8448. 10.1074/jbc.M109128200.CrossRefPubMed
47.
Itoh Y, Ito N, Nagase H, Evans RD, Bird SA, Seiki M: Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell. 2006, 17: 5390-5399. 10.1091/mbc.E06-08-0740.CrossRefPubMedCentralPubMed
48.
Sameni M, Dosescu J, Yamada KM, Sloane BF, Cavallo-Medved D: Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells. Mol Imaging. 2008, 7: 199-213.PubMedCentralPubMed
49.
Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS, Friedl P: Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 2007, 9: 893-904. 10.1038/ncb1616.CrossRefPubMed
50.
Yu M, Sato H, Seiki M, Thompson EW: Complex regulation of membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation by concanavalin A in MDA-MB-231 human breast cancer cells. Cancer Res. 1995, 55: 3272-3277.PubMed
51.
Finesmith TH, Broadley KN, Davidson JM: Fibroblasts from wounds of different stages of repair vary in their ability to contract a collagen gel in response to growth factors. J Cell Physiol. 1990, 144: 99-107. 10.1002/jcp.1041440113.CrossRefPubMed
52.
Gullberg D, Tingstrom A, Thuresson AC, Olsson L, Terracio L, Borg TK, Rubin K: Beta 1 integrin-mediated collagen gel contraction is stimulated by PDGF. Exp Cell Res. 1990, 186: 264-272. 10.1016/0014-4827(90)90305-T.CrossRefPubMed
53.
Carver W, Molano I, Reaves TA, Borg TK, Terracio L: Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol. 1995, 165: 425-437. 10.1002/jcp.1041650224.CrossRefPubMed
54.
Takino T, Tsuge H, Ozawa T, Sato H: MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix. Biochem Biophys Res Commun. 2010, 396: 1042-1047. 10.1016/j.bbrc.2010.05.059.CrossRefPubMed
55.
Takino T, Guo L, Domoto T, Sato H: MT1-MMP prevents growth inhibition by three dimensional fibronectin matrix. Biochem Biophys Res Commun. 2013, 436: 503-508. 10.1016/j.bbrc.2013.05.134.CrossRefPubMed
56.
Stehbens SJ, Paszek M, Pemble H, Ettinger A, Gierke S, Wittmann T: CLASPs link focal-adhesion-associated microtubule capture to localized exocytosis and adhesion site turnover. Nat Cell Biol. 2014, 16: 561-573. 10.1038/ncb2975.CrossRefPubMedCentralPubMed
57.
Wu X, Gan B, Yoo Y, Guan JL: FAK-mediated src phosphorylation of endophilin A2 inhibits endocytosis of MT1-MMP and promotes ECM degradation. Dev Cell. 2005, 9: 185-196. 10.1016/j.devcel.2005.06.006.CrossRefPubMed
58.
Phillip S, Bulbule A, Kundu GC: Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type I matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001, 276: 44926-44935. 10.1074/jbc.M103334200.CrossRef
59.
Deryugina EI, Ratnikov B, Postnova TI, DiScipio R, Smith JW, Strongin AY: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res. 2001, 263 (2): 209-223. 10.1006/excr.2000.5118.CrossRefPubMed
60.
Chattopadhyay N, Aparna M, Frei E, Chatterjee A: Human cervical tumor cell (SiHa) surface αVα3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity. J Cancer Res Clin Oncol. 2001, 127: 653-658. 10.1007/s004320100271.CrossRefPubMed
Metadata
Title
High threshold of β1 integrin inhibition required to block collagen I-induced membrane type-1 matrix metalloproteinase (MT1-MMP) activation of matrix metalloproteinase 2 (MMP-2)
Authors
Kulrut Borrirukwanit
Prasit Pavasant
Tony Blick
Marc A Lafleur
Erik W Thompson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2014
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-014-0099-3

Other articles of this Issue 1/2014

Cancer Cell International 1/2014 Go to the issue

Primary research

Stabilization of circulating tumor cells in blood using a collection device with a preservative reagent

Primary research

Curcumin inhibits leptin gene expression and secretion in breast cancer cells by estrogen receptors

Primary research

Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases

Primary research

Metformin inhibition of neuroblastoma cell proliferation is differently modulated by cell differentiation induced by retinoic acid or overexpression of NDM29 non-coding RNA

Primary research

Evaluation of stem-like side population cells in a recurrent nasopharyngeal carcinoma cell line

Primary research

Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: mutation analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits